Gadek Compares, Contrasts SARcode and TearSolutions

Tom Gadek, president and CEO of dry eye start-up TearSolutions, explains how his “religious vision quest” at SARcode Bioscience, the entity that developed the drug now sold as Xiidra by Shire, guides his leadership at TearSolutions, which just closed on an $8.5 million Series B. How will TearSolutions stand out from the crowd of new dry eye treatment developers?

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.